Clinical experience with triptans

Many drugs are now available for treating migraine attacks, including agents specifically indicated for this condition. Since 1990 sumatriptan, the first 5–HT(1B,1D) receptor agonist, was introduced and realized a real breakthrough in therapy; other agents of this class of drugs called triptans have...

Descripción completa

Detalles Bibliográficos
Autores principales: Zanchin, Giorgio, Dainese, Filippo, Mainardi, Federico, Maggioni, Ferdinando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2001
Materias:
Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3451834/
http://dx.doi.org/10.1007/s101940170021
_version_ 1782244401673666560
author Zanchin, Giorgio
Dainese, Filippo
Mainardi, Federico
Maggioni, Ferdinando
author_facet Zanchin, Giorgio
Dainese, Filippo
Mainardi, Federico
Maggioni, Ferdinando
author_sort Zanchin, Giorgio
collection PubMed
description Many drugs are now available for treating migraine attacks, including agents specifically indicated for this condition. Since 1990 sumatriptan, the first 5–HT(1B,1D) receptor agonist, was introduced and realized a real breakthrough in therapy; other agents of this class of drugs called triptans have more recently been used. All of them are effective in relieving the symptoms of migraine, but each exhibits pharmacological and/or clinical features that must be considered for the optimal care and management of the patient. We present here a short overview on the main clinical features of the triptans already in use in Italy.
format Online
Article
Text
id pubmed-3451834
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-34518342013-04-01 Clinical experience with triptans Zanchin, Giorgio Dainese, Filippo Mainardi, Federico Maggioni, Ferdinando J Headache Pain Therapy Many drugs are now available for treating migraine attacks, including agents specifically indicated for this condition. Since 1990 sumatriptan, the first 5–HT(1B,1D) receptor agonist, was introduced and realized a real breakthrough in therapy; other agents of this class of drugs called triptans have more recently been used. All of them are effective in relieving the symptoms of migraine, but each exhibits pharmacological and/or clinical features that must be considered for the optimal care and management of the patient. We present here a short overview on the main clinical features of the triptans already in use in Italy. Springer-Verlag 2001-09 /pmc/articles/PMC3451834/ http://dx.doi.org/10.1007/s101940170021 Text en © Springer-Verlag Italia 2001
spellingShingle Therapy
Zanchin, Giorgio
Dainese, Filippo
Mainardi, Federico
Maggioni, Ferdinando
Clinical experience with triptans
title Clinical experience with triptans
title_full Clinical experience with triptans
title_fullStr Clinical experience with triptans
title_full_unstemmed Clinical experience with triptans
title_short Clinical experience with triptans
title_sort clinical experience with triptans
topic Therapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3451834/
http://dx.doi.org/10.1007/s101940170021
work_keys_str_mv AT zanchingiorgio clinicalexperiencewithtriptans
AT dainesefilippo clinicalexperiencewithtriptans
AT mainardifederico clinicalexperiencewithtriptans
AT maggioniferdinando clinicalexperiencewithtriptans

Ejemplares similares